Business · 16/11/20261 min read
Fortvita Receives Its First Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
Summary
The opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is Fortvita's first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe PALO ALTO, Calif., Nov....